Further understanding of these mechanisms may eventually pave the way for improved personalized cancer therapy of PALB2 mutation carriers, and possibly also to carriers of functionally related cancer susceptibility gene defects in e.g., BRCA1 and BRCA2. The gene discussed is BRCA2; the disease is cancer.